{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-007928","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.791099+00:00","generated_at":"2026-06-01T03:45:57.439091+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved","bullets":["Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.","Hazard ratio 0.35 (95% CI 0.19-0.66, log rank p=0.0015).","Multikine targets low PD-L1 tumor expression, contrasting with checkpoint inhibitors like Keytruda.","Company working to commence FDA confirmatory Registration Study for Multikine."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-007928","json":"https://secwatch.observer/filing/0001654954-24-007928.json","markdown":"https://secwatch.observer/filing/0001654954-24-007928.md","text":"https://secwatch.observer/filing/0001654954-24-007928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/0001654954-24-007928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:45:57.439091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}